On average weight loss, Mounjaro tends to win. The tirzepatide behind it has produced larger reductions in body weight across trials than the semaglutide behind Ozempic. But that answer carries three caveats: these were separate studies rather than a direct duel, both drugs are approved for diabetes rather than weight loss, and the weight tends to return once treatment stops. So the real winner for any one person is the drug they can tolerate and afford to keep taking.
Are these even weight loss drugs?
This is the part people skip. Ozempic and Mounjaro are both approved for type 2 diabetes, not for weight management. The identical active molecules are sold under different brand names for obesity: semaglutide as Wegovy, tirzepatide as Zepbound. When a clinician prescribes Ozempic or Mounjaro for weight loss, that is an off-label choice. The FDA has published guidance on the semaglutide products and their marketed uses, and the distinction between the diabetes and weight brands is worth understanding before comparing them for a purpose neither label lists.
Reading the ozempic vs mounjaro question this way changes it. Much of the trial evidence for weight loss sits under the sibling brands, because those are the studies designed around body weight as the endpoint. The molecules are the same, but the approved names and doses are not.
What do the trials actually show?
Semaglutide’s weight data is well documented. The STEP program tested it in adults with overweight or obesity. In the STEP 3 trial, semaglutide paired with intensive behavioral therapy produced substantial average weight loss over 68 weeks. STEP 8 compared it against daily liraglutide, an older drug in the same family, and semaglutide came out clearly ahead. These are strong, consistent results for the semaglutide molecule.
Tirzepatide, the molecule in Mounjaro, acts on two gut hormone receptors rather than one. Its weight trials, including SURMOUNT-CN in Chinese adults with obesity, have reported larger average reductions than the semaglutide figures. That two-receptor mechanism is the leading explanation for the edge. The important discipline is that STEP and SURMOUNT are not the same study run side by side. Comparing their headline numbers gives a reasonable pattern, but it is not the same as a trial that randomized people to one drug or the other.
See also: Daily Nutrition Upgrade: Why Multivitamins for Men Support a Healthier Lifestyle
How do they compare at a glance?
| Factor | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Approved use | Type 2 diabetes | Type 2 diabetes |
| Mechanism | GLP-1 receptor | GLP-1 and GIP receptors |
| Weight-loss sibling brand | Wegovy | Zepbound |
| Average weight loss in trials | Substantial | Generally larger |
| Main side effects | Gastrointestinal | Gastrointestinal |
Does the weight stay off?
This is where the winner label gets slippery. The STEP 1 extension followed people after semaglutide was withdrawn and found that a large share of the lost weight returned over the following year, along with a reversal of several cardiometabolic gains. STEP 4 approached it from the other direction: people who continued semaglutide kept losing or held their weight, while those switched to placebo regained. SURMOUNT-4 showed the same shape for tirzepatide, with continued treatment maintaining the reduction and withdrawal leading to regain.
The lesson from both molecules is consistent. These are treatments for an ongoing condition, not a course you finish. Whichever drug produces the bigger number in month twelve loses that lead fast if the person cannot stay on it. That reframes the whole comparison around durability and access rather than peak effect.
What about side effects and tolerance?
Both drugs share a gastrointestinal profile: nausea, diarrhea, vomiting, and constipation, usually heaviest during dose escalation and often easing after. The prescribing information for the semaglutide products spells this out in detail, and the pattern is similar for tirzepatide. Individual tolerance varies enough that reported average rates only get you so far. Someone who feels constantly sick on the drug with the larger trial number will do worse in practice than on the one they can actually take every week.
Where does cost decide the winner?
List prices for both run above a thousand dollars a month, and insurance for weight loss is inconsistent, especially since the diabetes brands are off-label for this use. That pushes many people toward cash routes. Manufacturers now sell direct-to-patient at reduced self-pay prices, and telehealth services such as Ro, Hims and Hers, Henry Meds, and LillyDirect connect patients to prescribers and pharmacies. Some supervised practices publish flat monthly pricing for compounded versions of these molecules; for a plain-language rundown of how the two molecules differ before weighing those options, formblends.com lays out the mechanism and brand distinctions.
A word on compounded products, because they are everywhere in this market. Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and are not FDA-approved. They may carry the same active molecule as the brands, but they have not been through the process that generated the STEP and SURMOUNT evidence. That is a genuine difference in regulatory assurance, and it belongs in the decision with a prescriber, not treated as a generic swap.
So which one actually wins?
On the narrow question of average weight loss, tirzepatide, and by extension Mounjaro, has the stronger record. If someone had guaranteed access, tolerated both equally, and cared only about the number, that is the honest answer. But almost nobody meets those conditions. The drug you can afford month after month, tolerate without dropping out, and get prescribed for your situation is the one that will move your weight. A slightly smaller trial result you can sustain beats a larger one you have to abandon.
Key takeaways
- Mounjaro’s tirzepatide tends to produce larger average weight loss, but from separate trials, not a head-to-head.
- Both Ozempic and Mounjaro are approved for diabetes; weight-loss use is off-label, with Wegovy and Zepbound as the approved siblings.
- Weight returns after stopping either drug, so durability of access matters more than peak effect.
- Compounded versions are not FDA-approved, whatever molecule they contain.
Frequently asked questions
Which drug produces more weight loss?
Across separate trials, the tirzepatide molecule behind Mounjaro has tended to produce larger average weight loss than the semaglutide molecule behind Ozempic. These are different studies rather than a single head-to-head, so the gap should be read as a pattern, not a scoreboard.
Are Ozempic and Mounjaro even approved for weight loss?
No. Both are approved for type 2 diabetes. The same molecules are sold under separate brand names for weight management, and prescribing the diabetes brands for weight loss is an off-label decision made by a clinician.
Does weight come back after stopping?
Trial extensions show meaningful regain after people stop these medications. The weight loss is tied to continued treatment, which is one reason cost and long-term access matter as much as the size of the initial result.
Is a compounded version the same thing?
No. Compounded semaglutide or tirzepatide is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same active molecule but has not gone through the approval process behind the trial evidence.
How do side effects compare?
Both are mostly gastrointestinal: nausea, diarrhea, constipation, and vomiting, usually worst during dose increases. Tolerance varies by person, so the drug someone can stay on often matters more than small differences in reported rates.
